The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population  by Arici, Merve & Özhan, Gül
Saudi Pharmaceutical Journal (2016) xxx, xxx–xxxKing Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comSHORT COMMUNICATIONThe genetic profiles of CYP1A1, CYP1A2 and
CYP2E1 enzymes as susceptibility factor in
xenobiotic toxicity in Turkish population* Corresponding author. Fax: +90 2124400252.
E-mail address: gulozhan@istanbul.edu.tr (G. O¨zhan).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2016.06.001
1319-0164  2016 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Arici, M., O¨zhan, G. The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic
in Turkish population. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.06.001Arici Merve, O¨zhan Gu¨l *Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Beyazıt 34116, Istanbul, TurkeyReceived 18 April 2016; accepted 12 June 2016KEYWORDS
Genetic polymorphism;
Turkish population;
CYP1A1;
CYP1A2;
CYP2E1;
Cytochrome P450Abstract Evaluation and sequencing of heritable alterations in the human genome and the large-
scale identification of gene polymorphism for understanding the genetic background of individuals
in response to potential toxicants are provided by toxicogenetics. Cytochrome P450 (CYP) enzymes
play role not only phase I-dependent metabolism of xenobiotics but also metabolism of endogenous
compounds. CYP1A1, CYP1A2 and CYP2E1 enzymes, which are in phase I enzymes, are respon-
sible for metabolic activation and detoxification of several chemical compounds. In the present
study, it was determined the genotype and allele frequency of CYP1A1*2A, CYP1A2*1C,
CYP1A2*1F, CYP2E1 and CYP2E1*6, very common and functional single-nucleotide polymor-
phisms (SNPs), in Turkish healthy volunteers. It is believed that the determination of polymor-
phisms in the enzymes may be beneficial to prevent and reduce and adverse effects and death in
response to drugs. The allele frequencies of these genes were 24%, 9%, 33%, 42%, and 12%,
respectively. In the present study, the genotype profile of Turkish population was determined about
critical enzymes for xenobiotic metabolism. It is suggested that the obtained results might be ben-
eficial in order to dose adjustment of drugs and prevention of adverse reactions, and further inves-
tigation about mentioned enzymes and their polymorphisms.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Toxicogenetics provides the evaluation and sequencing of her-
itable alterations in the human genome and the large-scale
identification of gene polymorphism for understanding the
genetic basis for individuals’ differences in response to poten-
tial toxicants. This ensures to predict relative susceptibility of
an individual or populations to the adverse effects and relative
sensitivity to drugs and environmental chemicals associated
with these adverse effects (Orphanides and Kimber, 2003).toxicity
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over 90% of drug/xenobiotics and endogenous substrates.
Until now, fifty-seven CYP genes, which involve three families
(CYP1, CYP2 and CYP3) contributing to the oxidative meta-
bolism of various compounds, have been detected (Shastry,
2006). It is known that beside metabolizing several important
drugs, detoxification and bioactivation of environmental pro-
carcinogens and endogenous compounds are occurred by
CYP1 enzymes (Alessandrini et al., 2013).
CYP1A1 and CY1A2 are located on chromosome 15q24.1,
and expressed in liver and extra-hepatic tissue (Zanger and
Schwab, 2013). CYP1A1 enzymes are responsible for metabo-
lism of polycyclic aromatic hydrocarbons which are found in
tobacco smoke and a number of carcinogens. To date, approx-
imately twenty variant alleles of CYP1A1 have been identified
(Alessandrini et al., 2013). CYP1A2 has an important role not
only in metabolism of many drugs such as amitriptyline, theo-
phylline, and clozapine but also in the activation of some pro-
carcinogens and caffeine. There were more than fifteen alleles
identified for CYP1A2 (Alessandrini et al., 2013; Han et al.,
2002).
CYP2E1 is located on chromosome 10q.24 and expressed in
both of the liver and extra-hepatic tissues. It is involved in the
metabolic activation of many low molecular weight carcino-
gens and toxic compounds such as benzene, N-nitrosamines,
carbon tetrachloride, chloroform, vinyl chloride, tobacco
smoke, styrene and ethylene glycol. Moreover, CYP2E1 is a
major component oxidation of ethanol for production reactive
free radical which may lead to lipid peroxidation and affect
target tissue (Shahriary et al., 2012; Soya et al., 2005).
It is known that inter-ethnic differences are becoming more
critical factor for inter-individual variations in response to
drugs and other xenobiotic in terms of xenobiotic metabolism.
These differences ensure to respond differently because of dif-
ferent genetic backgrounds. Because phase I enzymes playing
the most important role in the oxidation of various chemical
compounds can activate the carcinogens and produce more
active metabolites with oxidation, the genetic differences may
risk in development of the various cancers (Bianchino et al.,
2011; O’Donnell and Dolan, 2009).
In the present study, we aimed to determine the genotype
profile of Turkish population in terms of important metaboliz-
ing enzymes for drugs and other xenobiotics, considering not
enough data for mentioned enzymes in Turkish population.
2. Materials and methods
DNA was isolated from venous blood samples of unrelated
160 Turkish healthy volunteers (88 females and 72 males; aged
20–65 years; location in European side) by High Pure PCR
Template Preparation Kit (Roche, Germany). The samples
were collected from Hospital of Istanbul University and Bag-
cilar Training and Research Hospital in 2013–2015. Genotyp-
ing of CYP1A1*2A (rs4646903, 6235T > C), CYP1A2*1C
(rs2069514, 3858G > A), CYP1A2*1F (rs76251, 163C > A),
CYP2E1 (rs3813867, -1295G> A) and CYP2E1*6
(rs6413432, 7632T > A) variants was performed by poly-
merase chain reaction (PCR) – restriction fragment length
polymorphism (RFLP) methods. The temperature was con-
trolled by thermal cycler (Gene Amp PCR System 9700;
Applied Biosystems, Carlsbad, CA, USA). RestrictionPlease cite this article in press as: Arici, M., O¨zhan, G. The genetic profiles of CYP1A
in Turkish population. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.10enzymes were obtained from New England Biolabs (Hitchin,
UK) and Fermentas (Vilnius, Lithuania). All participants pro-
vided informed consent and studies were approved by the
ethics committee of Istanbul University (2014/1546).
The Hardy-Weinberg equilibrium analysis was performed
to compare the observed and expected genotype frequencies
of subjects by using the chi-square (v2) test. Differences in
the CYP1A1*2A, CYP1A2*1C, CYP1A2*1F, CYP2E1 and
CYP2E1*6 genetic variants between Turkish and other ethnic
populations were also assessed by v2 test. A p value below 0.05
was considered statistically significant throughout the popula-
tion comparisons. All statistical analyses were performed using
Statistical Package for Social Sciences (SPSS) software (Ver-
sion 17, Chicago, USA). The other information about the
genetic variants studied is given in Table 1.
3. Result and discussion
In the present study, the frequencies of CYP1A1, CYP1A2 and
CYP2E1 gene variants in Turkish population were detected
(Table 2). There are some studies to investigate the effects of
difference related to these genes in drug response or xenobiotic
toxicity or disease (Barbieri et al., 2013; Grabar et al., 2008;
Zhou et al., 2009).
The distribution of CYP1A1*2A (C allele) is 10%, 41%,
34%, 19%, 28%, and 54% in European, American, South
Asian, Caucasian, Hispanic and Chinese, respectively (www.
hapmap.org). The Turkish population resembles Hispanic
population for this variant according to the present study.
The allele frequency of CYP1A2*1C (A allele) is 28%, 2%,
31%, 36%, 8%, 8%, 20% and 24% in East Asian, European,
African, American, South Asian, Caucasian, Hispanic and
Chinese, respectively. The frequencies of CYP1A2*1F (A
allele) are 50%, 67%, 68%, 56%, 76%, 53%, 70% and 76%
in Yoruba in Ibadan (Nigeria) (YRI), East Asian, European,
African, American, South Asian, Hispanic and Chinese,
respectively (www.hapmap.org). According to the mentioned
data, Turkish population resembles South Asian and Cau-
casian for CYP1A2*1C (A allele), and East Asian more than
European for CYP1A2*1F (A allele).
CYP1A1 and CYP1A2 are functional variants in both
development of diseases and toxicological risks induced by
environmental factors. Barbieri et al. (2013) investigated
whether there were any associations with some polymorphic
genes and hereditary medullary thyroid carcinoma (HMTC).
It was found that the carriers with both of CYP1A1*2A and
CYP1A2*1F homozygous variant allele had more increased
risk of HMTC. It was investigated whether there were any
associations of CYP1A1 polymorphisms with metabolic acti-
vation of 17b-estradiol and estrone. According to the study,
CYP1A1*2A had a significant higher catalytic activity for all
hydroxylation sites- particularly 2-hydroxylation and both
mentioned substrates and it was suggested there may be risk
of oestrogen-induced cancers and cardiovascular diseases with
CYP1A1 genotypes (Kisselev et al., 2005). Nie et al. (2011)
evaluated the effects of CYP1A1 genetic polymorphisms in epi-
dermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKI) in patient with non-small-cell lung cancer.
CYP1A1*2A polymorphism played a role as prognosis factor
strongly. In another study, it was evaluated the relation
between lung cancer and CYP1A1 polymorphism and was1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity
16/j.jsps.2016.06.001
Table 1 The PCR-RFLP conditions in the present study.
SNPs Primer sequences Annealing temperature
(C)
Restriction
enzyme
Digestion products
(bp)
CYP1A1*2A
(rs4646903)
F: 50 CAgTgAAgAggTgTAgCCgCT 30
R: 50 TAggAgTCTTgTCTCATgCCT 30
62 MspI W (TT): 343
M (CC): 134, 209
CYP1A2*1C
(rs2069514)
F: 50 gCTACACATgATCgAgCTATAC
30
R: 50 CAggTCTCTTCACTgTAAAgTTA
30
62.3 DdeI W (GG): 598
M (AA): 132, 466
CYP1A2*1F
(rs762551)
F: 50 CAACCCTgCCAATCTCAAgCAC
30
R: 50 CATggCTCTggTggACTTTTCA 30
66.5 ApaI W (CC): 1012
M (AA): 299, 713
CYP2E1
(rs3813867)
F: 50 TCgAggAAACTTgTggACCC 30
R: 50 gCAAgTCATTggTTgTgCTgC 30
65.1 SfcI W (GG): 329
M (CC): 35, 294
CYP2E1*6
(rs6413432)
F: 50 CgACATgTgATggATCCAggg 30
R: 50 TCgTgATCgCCTgCCTCA 30
64.7 DraI W (TT): 327
M (AA): 79, 248
bp: base pair; W: wild type; M: mutant type.
Table 2 Genotype frequencies of the gene variants in the
present study.
SNPs Genotype Genotype frequency n
(%)
Allele
frequency
CYP1A1*2A
(rs4646903)
T/T 83 (50.46) T: 0.76
C: 0.24T/C 62 (42.18)
C/C 2 (1.36)
CYP1A2*1C
(rs2069514)
G/G 131 (89.73) G: 0.91
A: 0.09G/A 5 (3.43)
A/A 10 (6.84)
CYP1A2*1F
(rs762551)
C/C 21 (14.00) C: 0.33
A: 0.67C/A 57 (38.00)
A/A 72 (48.00)
CYP2E1
(rs3813867)
G/G 76 (48.72) G: 0.58
C: 0.42G/C 27 (17.31)
C/C 53 (33.97)
CYP2E1*6
(rs6413432)
T/T 6 (3.87) T: 0.88
A: 0.12T/A 25 (16.12)
A/A 124 (80.00)
Susceptibility factor in xenobiotic toxicity 3found that CYP1A1*2A, which showed unusually high fre-
quency, associated with increasing lung cancer risk, especially
squamous-cell and small-cell lung cancer (San Jose et al.,
2010). Also, O¨zhan et al. (2014) found that there was the asso-
ciation between CYP1A1*2A and colorectal cancer in Turkish
population.
It was investigated the association of CYP1A2 polymor-
phisms with the inducing effect of heavy coffee consumption
in Serbian and Swedish populations. There was only one sig-
nificant association of heavy coffee consumption in carriers
of CYP1A2*1F homozygous variant for both the populations
(Djordjevic et al., 2010). Palatini et al. (2009) suggested that
there is the risk of hypertension association with coffee intake
and CYP1A2 polymorphism. According to the results, drink-
ing coffee is safe for carriers homozygous wild type allele while
carriers of variant allele (CYP1A2*1F) should not bePlease cite this article in press as: Arici, M., O¨zhan, G. The genetic profiles of CYP1A
in Turkish population. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.10consuming coffee. It was investigated whether there was any
relation between the inter-individual variation in CYP1A2
activity after smoking cessation and its genetic polymor-
phisms. There was a decreased enzyme activity from 1.0-fold
to 7.3-fold after smoking cessation and CYP1A2 activity was
1.55-fold higher in smokers (Dobrinas et al., 2011).
Grabar et al. (2008) investigated the relation between toxi-
city of leflunomide treatment and CYP1A2 polymorphisms in
patients with rheumatoid arthritis. It was found that carriers
with homozygous wild type allele for CYP1A2*1F had a 9.7-
fold higher risk compared with carriers with variant allele.
Similarly, Zhou et al. (2009) suggested the risk of toxicity
increased in carriers of wild type allele (C) during leflunomide
and olanzapine treatment.
As to CYP2E1, the distribution of CYP2E1 (C) is 20, 4, 6,
12, 1, 29, 20, 7, 0, 0 and 6% in East Asian, European, African,
American, South Asian, Han Chinese in Beijing, Japanese in
Tokyo, YRI, Caucasian, Hispanic and Chinese, respectively
(www.hapmap.org). According to the mentioned data, Turkish
population resembles East Asian and Chinese in Beijing more
than others. But the reason of little differences between the
populations and Turkish population might be less size of the
studied population. The variant allele frequency of CYP2E1*6
(A allele) is 27%, 11%, 7%, 17%, 20%, 6%, 17% and 15% in
EAS, European, African, American, South Asian, Caucasian,
Hispanic and Chinese (www.hapmap.org). According to the
mentioned data, Turkish population resembles European. In
a study, the allele frequency in Turkish population was found
to be 8.25% (Ulusoy et al., 2007).
Investigating association between CYP2E1 genetic poly-
morphisms and squamous cell carcinoma of the oesophagus,
the results showed that carriers of CYP2E1*6 heterozygous
variant allele had an increased risk for development of oeso-
phageal cancer. Also, it was extensive among cigarette smokers
and alcohol consumers (Li et al., 2005). Also, some studies
showed that this variant allele was associated with developing
breast and lung cancer (Uematsu et al., 1991; Shields et al.,
1996). Sugimura et al. (2006) evaluated the relation with oral
squamous cell carcinoma (OSCC) and many genetic polymor-1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity
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gous variant type had 2-fold higher risk of OSCC contrary
to heterozygous and homozygous wild type.
In conclusion, this study will contribute to represent their
genetic profile in terms of crucial metabolism enzymes because
there was no enough study about the genetic profiles of
CYP1A1, CYP11A2, and CYP12E1 in Turkish population.
The determination of polymorphisms in mentioned enzymes
might provide advantage for dose adjustment of some drugs
and protection from xenobiotics in order to prevention and
reduction in adverse effects and even death.
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